Pacira BioSciences, Inc. has published positive two-year results from a phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), the company’s investigational locally administered gene therapy for knee osteoarthritis (OA).
Published in the Annals of the Rheumatic Diseases, the study showed that PCRX-201, when administered as a single local administration via intra-articular injection into the knee, was well tolerated in patients with moderate to severe knee osteoarthritis.
Through two years of follow-up, exploratory outcome measures showed improvements in pain, stiffness, and function across all dose cohorts among patients who remained in the study.
Given the promising phase 1 results, phase 2 of the two-part multicentre study for PCRX-201 is underway.
